This approach highlights the possibility that selective MR1 agonists can enrich MAIT cell-mediated tumor immunity in MM and may also prove relevant in other tumors; however, in vivo models are essential to examine the stimulatory molecules to induce an anti-cancer effect of MAIT cells. This evidence concerns the gene MR1 and Miyoshi myopathy.